We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+49.04%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$18.8B
AUM Growth
+$4.11B
Cap. Flow
-$554M
Cap. Flow %
-2.95%
Top 10 Hldgs %
85.02%
Holding
117
New
8
Increased
21
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$227M
2
DBVT
DBV Technologies
DBVT
+$72.8M
3
KOD icon
Kodiak Sciences
KOD
+$69.2M
4
KRRO icon
Korro Bio
KRRO
+$19.2M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$15.7M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$627M
2
AMRN
Amarin Corp
AMRN
+$134M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$72.9M
4
NGNE icon
Neurogene
NGNE
+$39.4M
5
CBAY
Cymabay Therapeutics
CBAY
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.59%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLCM
76
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$3.45M 0.02%
267,782
– –
VKTX icon
77
Viking Therapeutics
VKTX
$3.86B
$3.41M 0.02%
425,000
– –
GTHX
78
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.36M 0.02%
127,236
– –
VYNE icon
79
VYNE Therapeutics
VYNE
$3.25M 0.02%
194
– –
HARP
80
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$3.17M 0.02%
21,429
– –
LKFT
81
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$2.7M 0.01%
13,072
-12,000
-48% -$2.22M
AUTL
82
Autolus Therapeutics
AUTL
$378M
$2.07M 0.01%
156,773
– –
NTLA icon
83
Intellia Therapeutics
NTLA
$1.48B
$1.89M 0.01%
128,538
– –
ANAB icon
84
AnaptysBio
ANAB
$1.52B
$1.84M 0.01%
113,086
– –
CTMX icon
85
CytomX Therapeutics
CTMX
$690M
$1.61M 0.01%
194,377
– –
IDYA icon
86
IDEAYA Biosciences
IDYA
$3.43B
$1.5M 0.01%
200,000
– –
GLMD icon
87
Galmed Pharmaceuticals
GLMD
$4.34M
$1.25M 0.01%
1,198
– –
RCUS icon
88
Arcus Biosciences
RCUS
$3.35B
$1.23M 0.01%
121,534
– –
ISEE
89
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.22M 0.01%
+141,750
New +$506K
TRIL
90
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.13M 0.01%
1,100,000
+594,738
+118% +$227K
CYPH
91
Cypherpunk Technologies Inc
CYPH
$64.1M
$1.1M 0.01%
97,845
– –
FSTX
92
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$969K 0.01%
153,286
– –
ADMS
93
DELISTED
Adamas Pharmaceuticals
ADMS
$654K ﹤0.01%
172,630
– –
INFI
94
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$557K ﹤0.01%
580,400
– –
AFMD
95
DELISTED
Affimed
AFMD
$548K ﹤0.01%
20,000
– –
DVAX
96
DELISTED
Dynavax Technologies
DVAX
$429K ﹤0.01%
75,000
– –
VIRX
97
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$188K ﹤0.01%
15,905
– –
AQST icon
98
Aquestive Therapeutics
AQST
$471M
– –
-99,600
Closed -$317K
CYCN icon
99
Cyclerion Therapeutics
CYCN
$14.9M
– –
-10,129
Closed -$2.46M
HALO icon
100
Halozyme
HALO
$9.87B
– –
-299,969
Closed -$4.65M
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Baker Bros. Advisors held 117 positions worth $18.8B, up 28% from $14.7B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q4 2019 filing shows 8 new, 21 increased, 10 reduced and 18 closed positions. Its largest new stake was Exact Sciences: 2,585,791 shares worth $239M. The largest sale was Genomic Health, Inc., an estimated $627M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Financials and Technology.

  • Baker Bros. Advisors's largest Q4 2019 buy was Exact Sciences: 2,585,791 shares worth $239M.
  • Baker Bros. Advisors added most to DBV Technologies in Q4 2019, an estimated $72.8M increase.
  • Baker Bros. Advisors's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $134M.
  • Baker Bros. Advisors fully exited Genomic Health, Inc. in Q4 2019, selling an estimated $627M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $18.8B portfolio in Q4 2019.
  • Baker Bros. Advisors opened 8 new positions and closed 18 in Q4 2019.
  • Baker Bros. Advisors's portfolio value rose 28% quarter-over-quarter to $18.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.